Table 2.
Cox UVA and MVA for cohort iC + CRT
| Variable | Cox UVA | Cox MVA | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Facility | ||||||
| Nonacademic | 1 | Ref | 1 | Ref | ||
| Academic | 0.76 | 0.65–0.89 | < 0.001 | 0.79 | 0.67–0.93 | 0.0045 |
| Age | ||||||
| < 65 | 1 | Ref | ||||
| ≥ 65 | 1.04 | 0.89–1.21 | 0.64 | |||
| Gender | ||||||
| Female | 1 | Ref | 1 | Ref | ||
| Male | 1.19 | 1.02–1.39 | 0.031 | 1.09 | 0.93–1.29 | 0.29 |
| Race | ||||||
| White | 1 | Ref | ||||
| Black | 0.86 | 0.68–1.10 | 0.23 | |||
| Other | 0.86 | 0.54–1.36 | 0.52 | |||
| Insurance | ||||||
| None | 1 | Ref | ||||
| Nonprivate | 1.07 | 0.57–2.02 | 0.82 | |||
| Private | 1.07 | 0.57–2.01 | 0.83 | |||
| Income | ||||||
| Above median | 1 | Ref | ||||
| Below median | 1.05 | 0.90–1.24 | 0.52 | |||
| Residential setting | ||||||
| Metro | 1 | Ref | ||||
| Urban | 1.00 | 0.79–1.26 | 0.98 | |||
| Rural | 1.35 | 0.80–2.25 | 0.26 | |||
| Charlson-Deyo Score | ||||||
| 0–1 | 1 | Ref | ||||
| ≥ 2 | 1.08 | 0.75–1.57 | 0.67 | |||
| Year of diagnosis | ||||||
| 2004–2007 | 1 | Ref | 1 | Ref | ||
| 2008–2011 | 0.95 | 0.71–1.28 | 0.75 | |||
| 2012–2015 | 0.67 | 0.50–0.89 | 0.0068 | 0.71 | 0.53–0.95 | 0.021 |
| Primary tumor site | ||||||
| Head | 1 | Ref | ||||
| Body | 0.87 | 0.73–1.04 | 0.12 | |||
| Tail | 1.25 | 0.78–2.01 | 0.35 | |||
| Tumor size (cm) | ||||||
| < 3.8 | 1 | Ref | 1 | Ref | ||
| ≥ 3.8 | 1.20 | 1.02–1.41 | 0.027 | 1.16 | 0.98–1.37 | 0.082 |
| Clinical N stage | ||||||
| 0 | 1 | Ref | ||||
| 1 | 1.15 | 0.98–1.34 | 0.091 | |||
| Chemotherapy | ||||||
| Single agent | 1 | Ref | 1 | Ref | ||
| Multi agent | 0.69 | 0.58–0.82 | < 0.001 | 0.77 | 0.64–0.92 | 0.0041 |
| Dose escalation | ||||||
| < 55 Gy | 1 | Ref | 1 | Ref | ||
| ≥ 55 Gy | 0.80 | 0.65–0.97 | 0.027 | 0.77 | 0.63–0.95 | 0.013 |
UVA univariate analysis, MVA multivariable analysis, HR hazard ratio, CI confidence interval, Ref reference